ChargePoint Technology is a market leading manufacturer and innovator of specialist high containment and sterile transfer valves.

The business manufactures and supplies high-performance containment and sterile transfer valves to the largest global pharmaceutical, bio-pharmaceutical and chemicals companies. Operating across Europe, Asia and North America, its patented technology is used in the development and manufacture of medicines and vaccines by the top 50 global pharmaceutical manufacturers, facilitating the safe transfer of highly-potent and sterile powders.

In January 2017 ChargePoint Technology secured investment from LDC to drive further international expansion. The investment by LDC, supporting Managing Director Chris Eccles and Sales Director Tony O’Sullivan in the buyout, will see LDC become a minority shareholder.

The business is capitalising on the strong and increasing demand for its solutions internationally, accelerating sales of its innovative AseptiSafe® Bio product, investing in the development of new products and on a targeted acquisition strategy to help it expand into adjacent sectors  requiring containment and sterile transfer solutions.

In 2017 ChargePoint Technology was recognised for exceptional profit growth in The Sunday Times Profit Track 100, placing 27th on the list. This marks the company’s debut in the league table, which ranks Britain’s privately owned companies with the fastest-growing profits over three years.

In September 2019 ChargePoint Technology announced strong sales growth after a year of new product launches and international success. The business reported 5% growth in sales to £12.9m (2017: £12.3m) for the year for December 2018, driven by strong trading results in its UK, European and Indian markets. It has also achieved several new contract wins in Canada, strengthening its presence further in the North American region and has grown its UK headcount by 15%, increasing from 74 to 85 people.

The continued support we received from LDC has been instrumental in allowing us to maintain growth, champion R&D and realise our global expansion ambitions. We have a number of exciting product developments in the pipeline, and look forward to evolving our offering even further.
Chris Eccles, CEO, ChargePoint